Performance of the SarQoL quality of life tool in a UK population of older people with probable sarcopenia and implications for use in clinical trials: findings from the SarcNet registry
dc.contributor.author | Witham, MD | |
dc.contributor.author | Heslop, P | |
dc.contributor.author | Dodds, RM | |
dc.contributor.author | Clegg, AP | |
dc.contributor.author | Hope, SV | |
dc.contributor.author | McDonald, C | |
dc.contributor.author | Smithard, D | |
dc.contributor.author | Storey, B | |
dc.contributor.author | Tan, AL | |
dc.contributor.author | Thornhill, A | |
dc.contributor.author | Sayer, AA | |
dc.date.accessioned | 2022-06-13T07:35:19Z | |
dc.date.issued | 2022-04-27 | |
dc.date.updated | 2022-06-10T17:20:20Z | |
dc.description.abstract | BACKGROUND: The Sarcopenia Quality of Life (SarQoL) questionnaire is a disease-specific sarcopenia quality of life tool. We aimed to independently assess SarQoL with a particular focus on its suitability as a clinical trial outcome measure. METHODS: We analysed data from the UK Sarcopenia Network and Registry. Measures of physical performance and lean mass were collected at baseline. SarQoL and the Strength, Assistance, Rise, Climb - Falls (SARC-F) questionnaire (to assess functional ability) were collected at both baseline and six-month follow-up. Global changes in fitness and quality of life at 6 months were elicited on seven-point Likert scales. Internal consistency was assessed using Cronbach's alpha. Responsiveness (Cohen's d and Guyatt coefficients) and minimum clinically important differences were calculated for participants reporting slight improvement or worsening in their global scores. Concurrent validity was assessed by correlating baseline SarQoL scores with measures of physical performance and functional ability. RESULTS: We analysed data from 147 participants, 125 of whom underwent follow up assessment; mean age 78 years; 72 (49%) were women. Internal consistency was good; Cronbach's alpha was 0.944 at baseline and 0.732 at telephone follow-up. Correlation between baseline and follow-up SarQoL was weak (r = 0.27; p = 0.03). The minimum clinically important improvement ranged from 5 to 21 points giving trial sample size estimates of 25-100 participants. SarQoL scores were moderately correlated with handgrip (r = 0.37; p < 0.001), SARC-F (r = - 0.45; p < 0.001), short physical performance battery (r = 0.48; p < 0.001) and 4-m walk speed (r = 0.48; p < 0.001). CONCLUSIONS: SarQoL has acceptable performance in older UK participants with probable sarcopenia and is sufficiently responsive for use in clinical trials for sarcopenia. | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.format.extent | 368- | |
dc.format.medium | Electronic | |
dc.identifier.citation | Vol. 22, article 368 | en_GB |
dc.identifier.doi | https://doi.org/10.1186/s12877-022-03077-5 | |
dc.identifier.uri | http://hdl.handle.net/10871/129918 | |
dc.identifier | ORCID: 0000-0001-7343-0149 (Hope, Suzy V) | |
dc.language.iso | en | en_GB |
dc.publisher | BMC | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/35477354 | en_GB |
dc.rights | © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | en_GB |
dc.subject | Minimum clinical important difference | en_GB |
dc.subject | Quality of life | en_GB |
dc.subject | Responsiveness | en_GB |
dc.subject | Sarcopenia | en_GB |
dc.title | Performance of the SarQoL quality of life tool in a UK population of older people with probable sarcopenia and implications for use in clinical trials: findings from the SarcNet registry | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-06-13T07:35:19Z | |
dc.identifier.issn | 1471-2318 | |
exeter.article-number | 368 | |
exeter.place-of-publication | England | |
dc.description | This is the final version. Available on open access from BMC via the DOI in this record | en_GB |
dc.description | Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request, subject to completion of a Data Access agreement with Newcastle University. | en_GB |
dc.identifier.eissn | 1471-2318 | |
dc.identifier.journal | BMC Geriatrics | en_GB |
dc.relation.ispartof | BMC Geriatr, 22(1) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_GB |
dcterms.dateAccepted | 2022-04-18 | |
dc.rights.license | CC BY | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-04-27 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-06-13T07:33:23Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-06-13T07:35:23Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2022-04-27 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.